Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies

Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies

Abstract Background The role of re-immunotherapy in advanced non-small cell lung cancer (NSCLC) remains unclear. No studies have evaluated the re-immunotherapy regimen including anti-cytotoxic T-lymphocyte antigen-4 antibody for lung cancer treatment. This study aimed to investigate the efficacy and...

Full description

Bibliographic Details
Main Authors: Takuma Imakita, Kohei Fujita, Takanori Ito, Zentaro Saito, Issei Oi, Osamu Kanai, Hiromasa Tachibana, Satoru Sawai, Tadashi Mio
Format: Article
Language:English
Published: Springer 2023-08-01
Series:Discover Oncology
Subjects:
Cytotoxic T-lymphocyte-associated protein-4
Tumor proportion score
Immune checkpoint inhibitor
Immune-related adverse event
Objective response rate
Online Access:https://doi.org/10.1007/s12672-023-00781-5

Similar Items

Similar Items